title: Is There a Future for AKT Inhibitors in the Treatment of Cancer?
abstract: An AKT inhibitor plus an antiestrogen exhibited no significant clinical activity in patients with ER(+)/HER2(-) breast cancer despite laboratory studies supporting an antitumor effect for both drugs combined. These results raise concerns about the development of AKT inhibitors in unselected patients whose tumors have unknown dependence on the PI3K/AKT pathway. Clin Cancer Res; 22(11); 2599-601. ©2016 AACRSee related article by Ma et al., p. 2650.
authors.affiliation: Breast Cancer Program, Vanderbilt-Ingram Cancer Center (VICC), Vanderbilt University, Nashville, Tennessee.
authors.forename: Valerie M
authors.initials: VM
authors.lastname: Jansen
authors.affiliation: Breast Cancer Program, Vanderbilt-Ingram Cancer Center (VICC), Vanderbilt University, Nashville, Tennessee.
authors.forename: Ingrid A
authors.initials: IA
authors.lastname: Mayer
authors.affiliation: Breast Cancer Program, Vanderbilt-Ingram Cancer Center (VICC), Vanderbilt University, Nashville, Tennessee. carlos.arteaga@vanderbilt.edu.
authors.forename: Carlos L
authors.initials: CL
authors.lastname: Arteaga
mesh_terms: D001943:Breast Neoplasms; D005260:Female; D006575:Heterocyclic Compounds, 3-Ring; D006801:Humans; D019869:Phosphatidylinositol 3-Kinases; D017698:Postmenopause; D051057:Proto-Oncogene Proteins c-akt; D011960:Receptors, Estrogen
chemical_list: D006575:Heterocyclic Compounds, 3-Ring; C548887:MK 2206; D011960:Receptors, Estrogen; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt